|
|
|
Volumn 82, Issue 4, 2000, Pages 336-
|
|
Economic disadvantages of palivizumab.
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTIVIRUS AGENT;
MONOCLONAL ANTIBODY;
PALIVIZUMAB;
COST;
ECONOMICS;
HUMAN;
INFANT;
NEWBORN;
NOTE;
VIRUS INFECTION;
ANTIBODIES, MONOCLONAL;
ANTIVIRAL AGENTS;
COSTS AND COST ANALYSIS;
HUMANS;
INFANT;
INFANT, NEWBORN;
RESPIRATORY SYNCYTIAL VIRUS INFECTIONS;
|
|
EID: 17344377610
PISSN: 14682044
EISSN: None
Source Type: Journal
DOI: None Document Type: Note |
|
Times cited : (2)
|
|
References (0)
|
